Seminar on Biopharmaceutical Quality Judgment Not Explainable by GMP to Be Held
IR Engineer Education Institute will hold an online seminar in June 2026 on biopharmaceutical quality judgment that cannot be fully explained by GMP. The seminar will provide a systematic learning experience on handling 'gray zone' quality, the difference between scientific and regulatory explanations, the relationship between GMP documents and CTD, and organizing corporate judgment and accountability.
📋 Article Processing Timeline
- 📰 Published: April 29, 2026 at 19:00
- 🔍 Collected: April 29, 2026 at 11:01
- 🤖 AI Analyzed: April 29, 2026 at 11:07 (6 min after Collected)
IR Engineer Education Institute will hold a public seminar to systematically learn about the differences between scientifically correct explanations and explanations acceptable to regulatory authorities, the relationship between GMP documents and CTD (Module 3), and the organization of company judgment and accountability, in order to address 'gray zone' quality in biopharmaceutical quality judgment, such as antibody drugs, regenerative medicine products, and nucleic acid drugs, which often cannot be clearly defined by standards and procedures alone.
In recent years, while biopharmaceuticals have developed alongside the advancement of medical technology, due to the characteristics of handling living cells and complex molecules, situations often arise where manufacturing results and quality characteristics cannot always be clearly defined as 'black or white.'
As a result, judgments are required where uncertainty remains even if standards and procedures are met, or where some out-of-specification data cannot be immediately rejected. This makes consensus building among departments (research, CMC, QA, clinical, contract manufacturing organizations, etc.) and organizing accountability challenging.
Seminar Outline
Course Name: Biopharmaceutical Quality Judgment Not Explainable by GMP
Format: Online (Zoom LIVE stream / Archived stream)
Date and Time:
[LIVE stream] Monday, June 22, 2026, 13:00 - 17:00
[Archived stream] June 24 - July 8, 2026
Tuition Fee: 49,500 yen (tax included) / per person (group discount available)
Instructor: Satoshi Suzuki, Instructor (Japan Pharmaceutical Support Association)
Course Details
This course will first organize the premises that make quality judgment difficult for biopharmaceuticals, then address situations where 'gray areas' often arise, such as transitions from early CMC to commercial CMC, process/raw material changes, technology transfer, and scale-up. Furthermore, from a regulatory perspective, it will explain the differences in roles between GMP documents and CTD (Module 3) and provide insights on how to make judgments and fulfill accountability as a site, QA, and organization.
Seminar Program
Chapter 1: Why is Biopharmaceutical Quality Judgment Difficult? [Background and Premise Organization]
Chapter 2: Where Do Gray Zone Qualities Emerge? [Typical Patterns]
Chapter 3: Reasons Why Scientifically Correct Explanations Are Not Accepted [Regulatory Perspective]
Chapter 4: Relationship Between GMP Documents and CTD [Exit for Quality Judgment]
Chapter 5: How Are Judgments Made in Practice? [QA/Organizational Reality]
Chapter 6: How Does a Company Make Judgments and Fulfill Accountability? [Summary/Practice]
Target Audience
Engineers and practitioners involved in research and development, CMC, manufacturing, quality assurance (QA), and quality control (QC) of pharmaceuticals and biopharmaceuticals.
Those involved in quality judgment and shipment release decisions (biopharmaceuticals / regenerative medicine products / nucleic acid drugs, etc.).
Those who understand GMP and various guidelines but are facing cases where judgment is difficult based solely on standards and procedures.
Those who feel challenged in coordinating quality judgments across departments.
Those struggling with quality explanations and data organization for approval applications and consultations with authorities (PMDA / FDA, etc.).
Project leaders/management層 who need a quality strategy for change control and post-market response.
*Click here for details of this seminar
https://nihon-ir.jp/seminar/biopharmaceutical_quality-assessment/
IR Engineer Education Institute will continue to provide practical knowledge and know-how through engineer education services (seminars, e-learning, training, publications) for the manufacturing industry.
Nihon IR Co., Ltd.
In addition to patent and intellectual property solutions with over 50 years of experience, we broadly develop highly specialized practical services based on technology, including technical information research and analysis, engineer education for the manufacturing industry, and technical content production.
◆Company HP: https://nihon-ir.jp/
◆IR Engineer Education Institute: https://engineer-education.com/
〒101-0033 15-1 Kanda-Iwamotocho, Chiyoda-ku, Tokyo, CYK Kanda-Iwamotocho 3F
TEL: 03-6206-4966
In recent years, while biopharmaceuticals have developed alongside the advancement of medical technology, due to the characteristics of handling living cells and complex molecules, situations often arise where manufacturing results and quality characteristics cannot always be clearly defined as 'black or white.'
As a result, judgments are required where uncertainty remains even if standards and procedures are met, or where some out-of-specification data cannot be immediately rejected. This makes consensus building among departments (research, CMC, QA, clinical, contract manufacturing organizations, etc.) and organizing accountability challenging.
Seminar Outline
Course Name: Biopharmaceutical Quality Judgment Not Explainable by GMP
Format: Online (Zoom LIVE stream / Archived stream)
Date and Time:
[LIVE stream] Monday, June 22, 2026, 13:00 - 17:00
[Archived stream] June 24 - July 8, 2026
Tuition Fee: 49,500 yen (tax included) / per person (group discount available)
Instructor: Satoshi Suzuki, Instructor (Japan Pharmaceutical Support Association)
Course Details
This course will first organize the premises that make quality judgment difficult for biopharmaceuticals, then address situations where 'gray areas' often arise, such as transitions from early CMC to commercial CMC, process/raw material changes, technology transfer, and scale-up. Furthermore, from a regulatory perspective, it will explain the differences in roles between GMP documents and CTD (Module 3) and provide insights on how to make judgments and fulfill accountability as a site, QA, and organization.
Seminar Program
Chapter 1: Why is Biopharmaceutical Quality Judgment Difficult? [Background and Premise Organization]
Chapter 2: Where Do Gray Zone Qualities Emerge? [Typical Patterns]
Chapter 3: Reasons Why Scientifically Correct Explanations Are Not Accepted [Regulatory Perspective]
Chapter 4: Relationship Between GMP Documents and CTD [Exit for Quality Judgment]
Chapter 5: How Are Judgments Made in Practice? [QA/Organizational Reality]
Chapter 6: How Does a Company Make Judgments and Fulfill Accountability? [Summary/Practice]
Target Audience
Engineers and practitioners involved in research and development, CMC, manufacturing, quality assurance (QA), and quality control (QC) of pharmaceuticals and biopharmaceuticals.
Those involved in quality judgment and shipment release decisions (biopharmaceuticals / regenerative medicine products / nucleic acid drugs, etc.).
Those who understand GMP and various guidelines but are facing cases where judgment is difficult based solely on standards and procedures.
Those who feel challenged in coordinating quality judgments across departments.
Those struggling with quality explanations and data organization for approval applications and consultations with authorities (PMDA / FDA, etc.).
Project leaders/management層 who need a quality strategy for change control and post-market response.
*Click here for details of this seminar
https://nihon-ir.jp/seminar/biopharmaceutical_quality-assessment/
IR Engineer Education Institute will continue to provide practical knowledge and know-how through engineer education services (seminars, e-learning, training, publications) for the manufacturing industry.
Nihon IR Co., Ltd.
In addition to patent and intellectual property solutions with over 50 years of experience, we broadly develop highly specialized practical services based on technology, including technical information research and analysis, engineer education for the manufacturing industry, and technical content production.
◆Company HP: https://nihon-ir.jp/
◆IR Engineer Education Institute: https://engineer-education.com/
〒101-0033 15-1 Kanda-Iwamotocho, Chiyoda-ku, Tokyo, CYK Kanda-Iwamotocho 3F
TEL: 03-6206-4966